Category Archive: Berthiaume Institute for Precision Health

Jan 29

Phage-Mimicking Antibacterial Nanoparticles Tackle Group A Streptococcal Infections In Vivo

We are excited to publish on our Phage-mimicking nanoparticles efficiently tackling Group A Streptococcus infections in mouse wound infection models in RSC Nanoscale Advances ( Thank you to Prof. Frank Castellino, Prof. Victoria Ploplis, and Deborah Donahue of the W.M. Keck Transgene Center for the in vivo studies. Thanks to Prof. Shaun Lee’s lab (Biology) …

Continue reading »

Oct 30

2nd Annual Berthiaume Institute for Precision Health’s Advisory Board Meeting

Great job by the Nallathamby lab (PDNANO) members Conor, Kevin and Carlie at presenting our work on antibacterials, and cancer therapeutics to the @ND_IPH advisory board! Great input from the advisory board members on possible collaborations and translational paths forward. #GoIrish#NDResearch#MDR#curecancer All three presenters have publications with us which formed the basis for these poster …

Continue reading »

Aug 14

1st Place Poster at the Military Health Sciences Research Symposium 2023 (Aug 14-17, Kissimmee, FL)

The Nallathamby group won 1st place at the DoD’s largest health conference (MHSRS’23) for our disruptive work tackling the biggest public health problem of Multidrug-resistant (MDR) bacterial infections. I am proud to represent ND among other distinguished participants! #GoIrish #NDresearch #mdr #MHSRS2023. Our work was titled, “Wound Healing Promoted by Broad-Spectrum, Phage Structure Mimicking, Synthetic …

Continue reading »

Jul 07

Congratulations to Ms. Johanna Olesk on Defending her MS (Bioengineering) ’23 Thesis

Congratulations to Nallathamby lab’s @JohannaOlesk on successfully defending her Masters thesis for Bioengineering in Summer 2023. Her thesis was titled ” Phage-Mimicking Nanoparticles Conjugated with Antimicrobial Peptides and Polymers as an Alternative to Antibiotic Treatment.” She passed with unanimous consent. We wish her all the best in her future undertakings. #WomenInSTEM#notredame#GoIrish Special mention to all …

Continue reading »

Jun 17

Translational Science to Impact Public Health was our Goal at Techconnect 2023

We were excited to present our work titled, “Biomimetic, Antibiotic Free, Nanoparticles for Agent Agnostic Broad Spectrum Antimicrobial Action including ESKAPE Pathogens” [Abstract 557] at the  2023 TechConnect World Innovation Conference in National Harbor, MD (June 19-21, 2023), as part of the Precision Health and Diagnostics symposium. Our talk was well received. We got lots of useful …

Continue reading »

May 23

Medical Technology Enterprise Consortium’s (MTEC) 8th Annual Meeting- Richmond, VA (May 23-24, 2023)

Nallathamby group’s work on “Phage-mimicking, Broad-spectrum, antibacterial nanoparticles” was showcased at MTEC’s annual meeting in Richmond, Virginia. I am proud to represent Notre Dame and the Berthiaume Institute for Precision Health at the 8th annual meeting of MTEC to learn firsthand the medical needs of the DoD. Our focus on combating antimicrobial resistance using phage …

Continue reading »

May 01

Argerie Guevara (CBE’23) Successfully Defends her Undergraduate Thesis

Congratulations to @Argerie Guevara (CBE’23) for taking the thesis option in her undergraduate research and passing it with unanimous consensus today.  Her thesis was titled, “PLGA nanoparticles formulations loaded with antibiotics induce sustained and controlled antibiotics release for prolonged antibacterial action against MRSA, and Pseudomonas aeruginosa FRD1,” and is currently being peer-reviewed for publication. Argerie is currently …

Continue reading »

Nov 16

Nallathamby Lab is one of 20 Participants Invited to Present Phage-Mimicking Antibacterial Nanoparticle Prototype at the Inaugural Joint Innovation Medical Symposium (JIMS) at Pope Army Airfield/Fort Bragg (Nov 16-17, 2022)

In recent combat theaters, despite advances in treating critical injuries leading to higher survival rates, there has been an increase in the number of infections linked to trauma, particularly those caused by bacteria resistant to multiple drugs 1,2.  Research from the Trauma Infectious Disease Outcomes Study indicates that 27% of those evacuated with injuries develop …

Continue reading »

Sep 16

Nallathamby Lab Presents Phage-Mimicking Antibacterial Nanoparticle Results at Military Health Sciences Research Symposium 2022 in Orlando, Florida (Sept 12-15, 2022)

We are losing in an antibiotic arms race with bacteria due to the emergence and global spread of new antibiotic resistance mechanisms.1,2 At current rates of antibiotics discovery and development we will eventually lose to antibiotic-resistant strains, and by 2050, antibiotics resistant strains of bacteria will kill more patients per year than all cancers combined. …

Continue reading »

Jul 07

CTSI-Think Tank Seed Funds our Efforts to facilitate CAR-T Therapy to Treat Solid Tumors.

Breast Cancer is the most widespread cancer and the second leading cause of cancer-related deaths among women in the U.S.A. As a treatment option, gene-modified T cells are under active therapeutic consideration for both hematological and solid malignancies.  As of 2016, there are 17 active TCR and 103 ongoing CAR-modified T cell studies registered through …

Continue reading »

Older posts «